Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor Zanubrutinib – Beigene

⟵ Back to Search Results

Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor Zanubrutinib

Beigene Study ID

BGB-3111-218

ClinicalTrials.gov ID

NCT05068440

China Drug Trials ID

CTR20210786

Study Overview

Sex: All

Age: 18 Years and older (Adult, Older Adult)

No Study Documents

Locations

Study Overview

Sex: All

Age: 18 Years and older (Adult, Older Adult)

No Study Documents